CONSOLIDATED STATEMENTS OF EARNINGS (UNAUDITED) (USD $) In Millions, except Per Share data, unless otherwise specified	3 Months Ended		9 Months Ended
	Sep. 30, 2012	Sep. 30, 2011	Sep. 30, 2012	Sep. 30, 2011
Income Statement [Abstract]
Net Sales	$ 3,736	$ 5,345	$ 13,430	$ 15,790
Cost of products sold	987	1,407	3,535	4,231
Marketing, selling and administrative	1,071	1,019	3,077	2,987
Advertising and product promotion	167	205	585	672
Research and development	951	973	2,822	2,831
Impairment charge for BMS-986094 intangible asset	1,830		1,830
Provision for restructuring	29	8	71	92
Litigation expense/(recoveries)	50		(122)
Equity in net income of affiliates	(40)	(71)	(150)	(215)
Other (income)/expense	(50)	(26)	(45)	(195)
Total Expenses	4,995	3,515	11,603	10,403
Earnings/(Loss) Before Income Taxes	(1,259)	1,830	1,827	5,387
Provision for/(benefit from) income taxes	(546)	475	250	1,358
Net Earnings/(Loss)	(713)	1,355	1,577	4,029
Net Earnings/(Loss) Attributable to Noncontrolling Interest	(2)	386	542	1,172
Net Earnings/(Loss) Attributable to Bristol-Myers Squibb Company	$ (711)	$ 969	$ 1,035	$ 2,857
Earnings/(Loss) per Common Share Attributable to Bristol-Myers Squibb Company:
Basic	$ (0.43)	$ 0.57	$ 0.62	$ 1.67
Diluted	$ (0.43)	$ 0.56	$ 0.61	$ 1.66
Dividends declared per common share	$ 0.34	$ 0.33	$ 1.02	$ 0.99